Dollex Agrotech (DOLLEX)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 54.20% shows significant insider ownership and alignment with minority shareholders.
• Latest quarter remained profitable with ₹27 Cr sales and ₹2 Cr net profit, implying roughly a 7.4% net margin.
• Price at ₹31.50 is closer to the 52-week low of ₹26 than the high of ₹43.55, so some pessimism already appears priced in.
• Listed in the sugar sector on NSE/BSE provides a defined, regulated investment vehicle for retail investors.

Concerns

• Sales growth is sharply negative at -28.32%, and profit growth is also down -23.39%.
• P/E of 31.40 is expensive for a company with declining earnings and zero dividend yield.
• Piotroski F-Score of 3/9 indicates weak financial health and potential red flags in operations, margins, or leverage.
• ROCE of only 6.90% is low, and the lack of ROE, book value, and debt/equity data limits any confidence in the balance sheet.

AI Analysis

At first glance, Dollex Agrotech is exactly the kind of small-cap sugar name I'd want to study. But the numbers stop me cold. Sales are down 28.32%, profits down 23.39%, and yet the market cap of ₹124 Cr is being valued at a P/E of 31.40. That is not a bargain; that is hope. Graham taught me to pay a fair price for a growing stream of earnings, but this stream is shrinking. The latest quarter shows ₹27 Cr revenue and ₹2 Cr net profit, which suggests some life, but one quarter does not make an investment case. ROCE of only 6.90% is below what I can get from a boring bond, and with no dividend yield, I am asked to wait for capital gains alone. Worse, the Piotroski F-score of 3 out of 9 points to deteriorating financial health. I have no ROE, book value, or debt-to-equity data, and for a value investor, flying blind on the balance sheet is unacceptable. Promoter holding at 54.20% is encouraging—owners have skin in the game—and the share price is closer to its 52-week low of ₹26 than its high of ₹43.55, but a falling price is not a catalyst. In the cyclical sugar business, low earnings can make a P/E look misleading; the question is whether the cycle is turning. Without evidence of margin stabilization, debt comfort, or earnings recovery, I cannot say this is a margin-of-safety purchase. It is a small, cyclical commodity play where I need more disclosure and a much cheaper price. I will keep it on my watchlist, not in my portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer